{"prompt": "['Protocol RS-001', 'Confidential', '5. Measure and record height and weight.', '6. Obtain and record vital signs.', '7. Collect blood for clinical laboratory tests (chemistry, hematology).', '8. Collect urine for pregnancy test (if child-bearing potential).', '11 ADVERSE EXPERIENCE REPORTING AND DOCUMENTATION', '11.1', 'Adverse Events', 'An AE is any untoward medical occurrence in a clinical investigation of a participant', 'administered a pharmaceutical product and that does not necessarily have a causal relationship', 'with the treatment. An AE is therefore any unfavorable and unintended sign (including an', 'abnormal laboratory finding), symptom or disease temporally associated with the administration', 'of an investigational product, whether or not related to that investigational product. An', 'unexpected AE is one of a type not identified in nature, severity, or frequency in the current', \"Investigator's Brochure or of greater severity or frequency than expected based on the\", \"information in the Investigator's Brochure.\", 'The Investigator will probe, via discussion with the participant, for the occurrence of AEs during', \"each participant visit and record the information in the site's source documents. All AEs are to\", \"be collected, from enrollment through end of the subject's study participation, and recorded in\", 'the participant CRF. Attribution will be unrelated, unlikely, possible, probably, or definite.', 'Taking into account the targeted population and the secondary endpoints of the study, Grade 1', \"and 2 seizures as defined by the National Cancer Institute's Common Terminology Criteria for\", 'Adverse Events (CTCAE) v5 will not be tracked as adverse events and will not be included in', 'the baseline patient assessment.', 'AE Severity', 'The CTCAE v5 should be used to assess and grade AE severity, including laboratory', 'abnormalities. If the experience is not covered in the modified criteria, the guidelines shown in', 'Table 3 below should be used to grade severity. It should be pointed out that the term \"severe\" is', 'a measure of intensity and that a severe AE is not necessarily serious.', 'Table 7. AE Severity Grading', 'Severity (Toxicity', 'Description', 'Grade)', 'Mild (1)', 'Mild; asymptomatic or mild symptoms; clinical or diagnostic observations only;', 'intervention not indicated', 'Moderate (2)', 'Moderate; minimal, local or noninvasive intervention indicated; limiting age-', 'appropriate Instrumental activities of daily living (e.g., preparing meals, using the', 'telephone, managing money)', 'Severe (3)', 'Severe or medically significant but not immediately life-threatening;', 'hospitalization or prolongation of hospitalization indicated; disabling; limiting', 'self-care activities of daily living (e.g., bathing, dressing, feeding self, using toilet,', 'taking medications)', 'Version 2', 'Version Date: October 31, 2018', 'Page 53 of 72']['Protocol RS-001', 'Confidential', 'Life-threatening (4)', 'Life-threatening consequences; urgent intervention indicated', 'Death (5)', 'Death related to AE', '11.2 Serious Adverse Experiences (SAE)', 'An SAE is defined as any AE occurring at any dose that results in any of the following', 'outcomes:', 'death', 'a life-threatening adverse experience', 'inpatient hospitalization or prolongation of existing hospitalization', 'a persistent or significant disability/incapacity', 'a congenital anomaly/birth defect', 'Other important medical events may also be considered an SAE when, based on appropriate', 'medical judgment, they jeopardize the participant or require intervention to prevent one of the', 'outcomes listed above.', '11.2.1 Serious Adverse Experience Reporting', 'The study site will document all SAEs that occur (whether or not related to study drug) on an', 'SAE Report Form. The collection period for all SAEs will begin after informed consent is', 'obtained and end after procedures for the final study visit have been completed.', 'Reporting of an SAE via SAE Report Form must be (1) sent to the site investigator, (2)', 'reviewed by the site investigator and (3) sent to the study chair and scientific director of AADi', 'within one business day of the site learning of the event. The study site will send the SAE', 'report by email (electronic or scanned copy). When available or requested, follow-up', 'information shall be reported via the SAE Report Form and sent to the site investigator and to the', 'study chair and scientific director of AADi.', 'In accordance with the standard operating procedures and policies of the local Institutional', 'Review Board (IRB) and federal regulations, the site investigator will report SAEs to the IRB.', '11.3', 'Medical Monitoring', 'It is the responsibility of the Principal Investigator to oversee the safety of the study at his/her', 'site. This safety monitoring will include careful assessment and appropriate reporting of adverse', 'events as noted above, as well as the construction and implementation of a site data and safety-', 'monitoring plan. Medical monitoring will include a regular assessment of the number and type of', 'serious adverse events.', '11.4', 'Monitoring suspected toxicities for discontinued participants', 'Participants whose treatment is permanently discontinued due to an adverse event or abnormal', 'laboratory value suspected to be related to ABI-009 must be followed at least weekly until the', 'adverse event or abnormal laboratory resolves or returns to grade 1. If a participant requires a', 'dose delay of >3 weeks from the intended day of the next scheduled dose, then the participant', 'must be discontinued from the study.', 'Version 2', 'Version Date: October 31, 2018', 'Page 54 of 72']\n\n###\n\n", "completion": "END"}